BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

LAB International (CC:LAB) Announces The Signing Of The Definitive Purchase And Sale Agreement For The Acquisition Of PharmaForm LLC; Management Team Strengthened


1/11/2007 12:31:10 PM

MONTREAL, Canada, Jan. 11 /PRNewswire-FirstCall/ - LAB International Inc. ("LAB"), a drug development company focused on developing therapies for the inhalation and pain markets, today announced it has signed the definitive Purchase and Sale Agreement for the acquisition of all of the outstanding membership interests of PharmaForm L.L.C., a privately held company headquartered in Austin, Texas. The transaction is expected to close within the next 2 weeks. U.S. $7.5 million in cash and U.S. $4.375 million in LAB shares will be paid at closing. The Sellers will be eligible for additional payments in LAB shares upon completion of certain milestones relating to PharmaForm's drug development programs reaching specific clinical trial stages.

"Now that the acquisition of PharmaForm is completed, we look forward to the rapid advancement into clinical trial stages of additional and complementary high potential platforms and products." commented Dr. Halvor Jaeger, CEO of LAB International.

Dr. Roman Denk has been appointed Vice-President Corporate Support replacing Mr. Hanns-Christian Palka who left the Company to pursue other interests. Dr Denk has more than 15 years of experience in the medical sciences industry most recently as founder and managing shareholder of CeloNova BioSciences Germany, GmbH, (www.CeloNova.com) (previously Polyzenix GmbH, Germany), an innovative medical device company. Dr. Denk holds a Doctorate in Chemistry from the University of Ulm and has a strong intellectual property rights background.

About PharmaForm

Headquartered in Austin, Texas, PharmaForm is a leading specialty contract service provider offering a portfolio of innovative technologies in drug product development, manufacturing and analytical testing. Through its diverse offerings, PharmaForm delivers drug product solutions that help clients reduce development costs and accelerate time-to-market. PharmaForm is currently expanding its drug product pipeline based upon its expertise in hot-melt extrusion and solids processing.

About LAB International

LAB is a drug development company focused on the growing multi-billion dollar inhalation market. Its lead product, for the treatment of breakthrough cancer pain, is a fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry powder inhaler platform. Its pipeline also includes therapeutics for asthma, COPD, and growth hormone deficiencies.

LAB's common shares trade on The Toronto Stock Exchange ("TSX") under the symbol "LAB", on the Frankfurt Regulated Unofficial Market under the symbol "LD9.F" and on XETRA under the symbol "LD9.DE" with 76.2 million shares outstanding.

This news release contains certain forward-looking statements that reflect the current views and/or expectations of LAB International Inc. with respect to its performance, business and future events. Such statements are subject to a number of risks, uncertainties and assumptions. Actual results and events may vary significantly.

LAB INTERNATIONAL INC.

CONTACT: visit LAB's website at www.labinc.ca, or contact: FredericDumais, Vice-President, Investor Relations, (514) 315-3330, Fax: (514)315-3325, dumaisf@labinc.ca



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES